Member Info for Hedgehog100

Looks like Minnowtech is moving strongly into its commercialisation phase:

BUGSS @BUGSSlab·3h
"Learn how Minnowtech uses sonar to help aqua-farmers raise the shrimp that ends on your dinner plates. This free event happens THIS WEEK online! Register here: hxxps://wfy.ai/3srRrkU #minnowtech #shrimp #aquaculture "
https://twitter.com/hashtag/minnowtech?src=hashtag_click

Which is great news for OTAQ:

15th Dec 2021 7:00 am RNS Interim Results
"... OTAQ's investment in the shrimp industry through Minnowtech LLC will see additional revenue in the second half of the year with 27 sonars delivered to Minnowtech by December 2021 and an order placed for 100 more to be delivered in Q4. This will deliver over GBP0.2m of revenue. Minnowtech's business plans forecast rollout of a high three figure number of sonars, which will be supplied by OTAQ, in the 2022 calendar year. ..."
https://www.lse.co.uk/rns/OTAQ/interim-results-pjcbcd45x2fm49r.html

So 127 OTAQ sonars to Minnowtech will deliver over £200K. of revenue to OTAQ in its H2 to 31.3.22.

If a high three figure number of sonars are expected to be supplied in 2022, say 800, then that would mean 700 in April-December 2022.
Which on the basis of over £200K. for 127, would suggest over £1.1M. for a further 700.

Don,

Since 9.40a.m., the number of GENI sells today shown on LSE has outnumbered the number of GENI buys.

It was then 13 buys, 14 sells, & 2 unknowns.

The initial buying was enough to cause a rise, and the falling since then has coincided with the small selling.

I think that would be enough to cause the fall, especially in these markets.

But of course any share can potentially have delayed trades showing at the end of the day.

If there's large delayed trades at the end of the day, they can match each other, i.e. a large delayed sale, and a large delayed buy.

So I'm not saying that there won't be delayed trades showing at the end of today, just that the retail selling looked enough to me to cause the fall.

8th Feb 2022 7:00 am RNS Positive results for Lipid inCode in NHS study
https://www.lse.co.uk/rns/GENI/positive-results-for-lipid-incode-in-nhs-study-cw5qtv1wyp1hpj6.html

The company well is on course, and is cash-rich after raising £17M. in its IPO last summer.

The problem is obviously the markets, not the company.

I can understand why people would want to increase their cash % of their investment accounts at the moment, but I would think GENI would be one of the last choices to sell.

It's clearly very undervalued, with no cash or business concerns, and little exposure to challenges like supply chains difficulties and inflation.

And higher interest rates will give it a greater return on its cash.

It's sad that poor market sentiment is currently weighing on it, but things in investment can change very quickly.

Additional positive FDA news could be a real stimulus, and the final results should be soon, after which the directors will be able to buy.

In addition, a takeover at this depressed price is a real possibility.

The largest trade shown today is for £4,353.

It looks to me like small retail sales, not a large seller, in line with weak markets at the moment.

"Announcing Osirium PAM v8.0 - Accelerates the Route to Zero Trust

Major Update to Osirium PAM

Reading, UK 19th January 2022 – Osirium (AIM: OSI.L),the UK’s leading Privileged Access Management (PAM) company, today announced a major new update to its PAM solution that brings a new level of protection for powerful administrator accounts with the release of Osirium PAM v8.0. This new release focuses on two critical new and enhanced capabilities making it easier for businesses to adopt zero-trust security strategies: scheduled and approved access to administrator accounts, and built-in multi-factor authentication(MFA).

Zero-trust is a rapidly growing security model in many organisations. According to MarketsandResearch.com, “The global zero trust security market size is expected to reach USD 59.43billion by 2028, registering a CAGR of 15.2% from 2021 to 2028”.

Osirium CEO and Co-Founder David Guyatt said, “Osirium has always focused on making PAM easier. At a time when more staff are working remotely than ever before, it’s critical that every IT leader prioritises both security of access and enabling teams to work with minimum delay.” ..."

https://www.osirium.com/news/announcing-osirium-pam-v8-0-accelerates-the-route-to-zero-trust

Osirium @Osirium · 4 Feb
"The @osirium PAM v8.0 release was quite a big deal! Somehow CTO Andy Harris has managed to cram it into 80 seconds! #cybersecurity #pam [...] Learn more at hxxps://www.osiriumcom/pam "
https://twitter.com/osirium

19 JANUARY 2022
"Announcing Osirium PAM v8.0 - Accelerates the Route to Zero Trust
New PAM release from Osirium delivers pre-approval for just-in-time access and built-in MFA. Make zero trust easier."
https://www.osirium.com/news

COMPARE & CONTRAST: CROSSWORD CYBERSECURITY v. OSIRIUM TECHNOLOGIES

The CCS v. OSI full year results look quite comparable ... but for CCS shares you're paying over nine times as much. -

CCS:
27th Apr 2021 7:00 am RNS 2020 Annual Results; AGM Notice; Board Changes
"... Delivered 25% revenue growth to GBP1.6m, despite the toughest economy in recent memory. ...
Loss of GBP2.3m and GBP1.0m closing cash. ..."
https://www.lse.co.uk/rns/CCS/2020-annual-results-agm-notice-board-changes-yfacggt05pxodct.html

OSI:
11th Jun 2021 7:00 am RNS Final Results
"... Total recognised revenue increased by 22% to GBP1.43 million ...
Reduced operating loss of GBP2.88 million ...
... Cash balances at 31 December 2020 of GBP1.48 million ..."
https://www.lse.co.uk/rns/OSI/final-results-v0wdczyeqclzjvu.html

Current CCS s.p.: 34.5p, market cap. £25.86M.

Current OSI s.p.: 9.5p, market cap. £2.79M.

Comparing OSI to other cybersecurity companies really highlights OSI's relative attractions.

And it could go much higher - look at the STAR placing lat October at a massive premium.

In a placing, shares tend to revert towards their true value: which here, is far higher

In contrast, Deepmatter was massively overvalued, with a market cap. far higher than OSI's, but losses far higher, and revenues far less.

Intelligent investors, such as those who fund placings, will be able to tell the difference.

The potential here hasn't changed, you're now just paying far less for it.

The only other thing that' s changed is that you've dumped you're shares and wish to rebuy.

And you're ruining your reputation on LSE, which was previously not bad!

Recent Share Trades for Osirium Tech (OSI)
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
04-Feb-22 16:34:56 10.00 5,000 Buy* 9.00 10.00 500.00 O
04-Feb-22 14:09:39 9.90 152,464 Unknown* 9.00 10.00 15.09k O

Interesting large buy this afternoon, for over 100 times the market size (1,500 shares).

You often find that a large trade marks the bottom, be it a buy or sell, and this could be just such a signal.

Nice to see SYS move up today, its first blue day since November.

Though at its current s.p. of 27p, its market cap. is still just £13.19M. - less than its annual revenue.

For a profitable, cash-rich IT company, with great growth prospects, that looks too cheap, and a good recovery from this level looks very possible.

"Concerned that fast growing companies come back to the market for more cash."

Pete,

PODP raised about £100M. gross from its November IPO for the company.

That's different from many IPOs, where a lot of the money raised sometimes goes to selling shareholders.

There were no net selling shareholders, & the boss invested millions of pounds.

If and when the company wishes to raise more (and it could get taken over first), I would think that the company would have progressed significantly, and that stock market conditions would be very different.

Current market capitalisation at 9.5p: £2.79 million.

Surely its worth far more than this?!

Investors into AIM placings are well used to loss-making companies, as those are the types that are usually placing.

And I would think that, compared to alternate investments, this will look attractive to them.

This is a company that really could get taken over for multiples of its current s.p.

Tesla has rebounded about 10% in the last week, and I would expect PODP to rebound too.

PODP was at this level when it started conditional trading three months go, and it quickly made some great gains.

The company's final results are due two weeks tomorrow, which I think should provide a good boost, especially as the company hasn't been helped by its lack of newsflow.

There's a lot of great progress going on behind he scenes, but this need to be conveyed to the market.

31st Jan 2022 7:00 am RNS Board Changes and Update

... Operational updates

In addition to these Board changes, Ovoca Bio today announces the following updates:

· Seventy percent of patients have now been enrolled in the Phase II dose ranging study assessing Orenetide (BP-101) being conducted in Australia and New Zealand. While the COVID-19 pandemic has significantly impact clinical trial related activities globally and has affected our trial, the Company intends to complete recruitment of participants in H1 2022.

· The Marketing Authorization ("MA") application for orenetide is still under review by the Russian Ministry of Health (the "Minzdrav"). While Ovoca cannot be definitive about timelines, management remains optimistic with regard to approval perspectives for Orenetide in Russia and is hopeful that the review process will be completed shortly. A further announcement in relation to the approval process will be released by the Company as and when appropriate. ...

https://www.lse.co.uk/rns/OVB/board-changes-and-update-0gr8yy87jnzc2v0.html

31st Jan 2022 7:00 am RNS Board Changes and Update

Dublin, Ireland, 31 January 2022 - Ovoca Bio plc (LSE: OVB; ISE: OVXA) a biopharmaceutical company with a focus on women's health, is pleased to announce the appointment of Dr. Kristina Zakurdaeva, MD, PhD as an Independent Non-Executive Director effective immediately. Dr. Zakurdaeva succeeds Chris Wiltshire on the Board. Mr. Wiltshire has resigned from the Board and role of Chief Business Officer with immediate effect to pursue other business interests.

Dr. Zakurdaeva currently serves as CEO of New York-based Incuron (Buffalo, NY), a drug development company in the oncology sector. Before Incuron, she served as Chief Medical Officer at Gero (Singapore/Russia), a drug discovery company focused on aging and aging-related diseases, where she developed clinical strategy for the company's pipeline.

Prior to Incuron, Kristina worked as a Scientific Advisor at Bristol-Myers Squibb and later headed oncology and immunology R&D projects in the Biomed Cluster of the Skolkovo Foundation (Moscow) where she successfully launched the Cancer Center of Excellence. Dr. Zakurdaeva is a Founder and Chair of the Foundation Board for the Foundation for Cancer Research Support (Russia) and has authored numerous, recent, peer-reviewed publications and co-authored a scientific discovery in genetics. Kristina holds a medical doctor degree in internal medicine and hematology, as well as a PhD in genetics of acute leukemia.

Kirill Golovanov, Chief Executive & Interim Chairman of Ovoca Bio, commented: "We are extremely excited to appoint Kristina Zakurdaeva to our Board. Her appointment, following that of Anastasia Levashova, adds to the complementary skill sets and breadth of perspectives on the Board of Ovoca Bio. Dr. Zakurdaeva brings extensive expertise in biotech and drug development in the USA and globally. Her strong clinical and scientific background, as well as business development experience, will be invaluable in the next stages of Ovoca Bio's journey. On behalf of the Company, I would also like to thank Chris for his contribution to the Board and as Chief Business Officer." ...

https://www.lse.co.uk/rns/OVB/board-changes-and-update-0gr8yy87jnzc2v0.html

100-bagger Tesla has fallen back recently in line with the EV sector, but still has a market cap of US$0.941 trillion, which is about thirty times its full year revenues:

Market Cap US$ 941,407,914,913
Latest Fiscal Revenue US$ 31,536,000,000

PODP's 2022 revenue could exceed £100M., and could be up about ten-fold in just a few years from its 2018 level.

At that point, valuing PODP at about ten times sales would I think be quite possible, which would give it a market cap. of about £1 billion ... which is nearly three times its current level.

"KEVIN DECAMP’S STORY OF HIS 100-BAGGER WITH TESLA
Dec 22, 2020, 1:19 pm"
https://www.valuewalk.com/kevin-decamp-100-bagger-tesla/

Thanks Swissydog - that's very helpful.

So within a few years GENI's profits could be greater than it's current market cap. ...nice!

27th Jan 2022 7:00 am RNS Half-year Report

" ...HCM revenue increased by 32% to £5,458,000 (H1 FY21: £4,139,000)

It has been a strong first half of the year in the HCM business, with the US market being particularly successful with revenue of £4,209,000 (H1 FY21: £2,605,000), a 62% increase. This has been driven by contracts with large US software providers.

We have continued to build on our strong relationships with our existing customers and are engaging with several Tier 1 target HCM software providers and potential clients. They are speaking to us about the possibility of GT Clocks (the Company's trading name in the US) providing its next generation hardware and, due to the easing in the travel restrictions, we have completed more face to face meetings again. We also delivered the first orders for our newest Clock (GT8), which launched in April 2021.

In our Rest of World HCM business, we have also continued negotiations with several Tier 1 clients for both products and services. Whilst we have seen a 19% reduction in revenue in this area, we have onboarded some key staff to lead the growth of this sector moving forwards.

Product Development - Hardware and Software

We continue to invest in development of both hardware and software platforms to support our anticipated further growth in the HCM market globally. Our hardware, electronics, and embedded software teams have been working on updates to our facial recognition and temperature detection software and our next clock. Additionally, focus remained on developing added-value services, intended to be provisioned on an 'as a service' basis, increasingly cloud-based, aiding software vendors to reap additional value from their hardware post-deployment.

We continue to see growth in the HCM market being facilitated through the technology 'drivers' of high-speed internet availability and the subsequent mass shift to Cloud based computing. We are developing our HCM software platforms with a Cloud and Application Programming Interface ("API") first approach. A Cloud and API first approach prioritises utilising a Cloud infrastructure along with APIs to provide seamless connectivity and integration between back-end and front-end systems for customers.

During the period, three of our longstanding US HCM clients agreed to subscribe to our Cloud provisioned software, remotely connecting new and/or existing timeclock devices with our platform. By the close of the period, c. 5,400 'edge' devices globally were connected to our platform and we expect this number to more than double by the end of the financial year. The upgraded version of our Cloud provisioning software is due to be launched in Spring 2022 which will further drive subscription growth. ..."

https://www.lse.co.uk/rns/NWT/half-year-report-xkas3fz5xzbt7ae.html

The human capital management (HCM) business looks like a strong success story, and with more contract wins in the offing, and exciting product development.

15th Oct 2021 7:00 am RNS Trading update, AGM, Investor Meet, capital reorg
" ... The Company has sought to bolster levels of stock held in order to build in a buffer to ensure that the global supply chain issues do not impact the Group's ability to fulfil existing and anticipated client orders, and to better withstand the risk of future supply-chain disruption. This increased working capital outlay, coupled with the significantly higher freight costs and increased component costs, has negatively impacted gross margins and cashflows in the first four months of the year ending 30 April 2022. ..."
https://www.lse.co.uk/rns/NWT/trading-update-agm-investor-meet-capital-reorg-f7q0dwsjifafltf.html

The increasing of levels of stock held is a one-off cost, not an ongoing cost, because the levels won't have to be continually increased. Once they are increased, ongoing stock replacement can then be at normal levels.

Indeed, once supply chain issues are resolved as the pandemic subsides, levels of stock held can then be decreased again to normal levels, providing a corresponding cash benefit to match the prior costs of increasing them.

It looks to me that these first half results are the nadir, and the outlook going forward is far more positive.

"This is due to continued pressure on margins as the supply chain issues push up purchase and freight costs, coupled with additional administrative costs as we have setup the business for further future growth."

Supply chain issues are widely expected to abate this year as the pandemic subsides, and in the meantime the company is investing for further growth.

Though premium placings per se are quite rare, for hugely undervalued companies they are actually par for the course.

On 22nd. October last year I had two of my shares announce such placings in one day, with those two finishing as the top two risers that day. -

"LSE % Gainers Top Lists
EPIC Name %
IRON Ironveld +52%
STAR Starcom +32%"

STAR had also been hit by supply chain issues.